Risedronate Sodium NDC 0093-3099

NDC codes

FDA NDC Directory

Product NDC (as listed)0093-3099Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00093-3099Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0093-3099-56	00093309956	30 TABLET, FILM COATED in 1 BOTTLE (0093-3099-56)Marketed from Jun 1, 2015

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Risedronate Sodium
Generic name (nonproprietary): risedronate sodium
Active ingredients: Risedronate sodium monohydrate — 5 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Teva Pharmaceuticals USA, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 077132
Marketing start: Jun 1, 2015
Listing expires: Dec 31, 2027
Other FDA classes: Diphosphonates (Chemical structure)
Identifiers: Product ID 0093-3099_641c2a59-be2b-4246-8990-b7bf563012beSPL ID 641c2a59-be2b-4246-8990-b7bf563012beSPL set ID dddcd321-4d2e-4643-bf3c-7b752b33ba39RxCUI 905024, 905032, 905041, 905092, 905100UNII F67L43UT5C
Pharmacologic class: Bisphosphonate

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400093309956 followed by a unit qualifier and the quantity

Package 00093-3099-56. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 30, 2026.

Indications (excerpt from the label)

Risedronate sodium tablets are a bisphosphonate indicated for: Treatment and prevention of postmenopausal osteoporosis ( 1.1 ) Treatment to increase bone mass in men with osteoporosis ( 1.2 ) Treatment and prevention of glucocorticoid-induced osteoporosis ( 1.3 ) Treatment of Paget’s disease ( 1.4 ) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use. ( 1.5 ) 1.1 Postmenopausal Osteoporosis Risedronate sodium tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women. In postmenopausal women with osteoporosis, risedronate sodium tablets reduce the…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 077132

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 077132
Product	Strength	Form · route	Labeler	Product NDC
Risedronate Sodium	Risedronate sodium monohydrate 35 mg/1	Tablet, Film coatedOral	Teva Pharmaceuticals USA, Inc.	0093-3098
Risedronate Sodium	Risedronate sodium monohydrate 30 mg/1	Tablet, Film coatedOral	Teva Pharmaceuticals USA, Inc.	0093-3100